

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2013/190072 A1

(43) International Publication Date

27 December 2013 (27.12.2013)

WIPO | PCT

(51) International Patent Classification:

C12Q 1/00 (2006.01)

(21) International Application Number:

PCT/EP2013/062950

(22) International Filing Date:

20 June 2013 (20.06.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

13/529,890 21 June 2012 (21.06.2012) US

(71) Applicant: LIFESCAN SCOTLAND LIMITED [GB/GB]; Beechwood Park North, Inverness, Inverness-shire IV2 3ED (GB).

(72) Inventors: WHYTE, Lynsey; Beechwood Park North, Inverness, Inverness-shire IV2 3ED (GB). SLOSS, Scott; Beechwood Park North, Inverness, Inverness-shire IV2 3ED (GB). WHITEHEAD, Neil; Beechwood Park North, Inverness, Inverness-shire IV2 3ED (GB). MCCOLL, David; Beechwood Park North, Inverness, Inverness-shire IV2 3ED (GB). SMITH, Antony; Beechwood Park North, Inverness, Inverness-shire IV2 3ED (GB).

(74) Agents: TUNSTALL, Christopher Stephen et al.; Carmaels & Ransford, One Southampton Row, London WC1B 5HA (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))



WO 2013/190072 A1

(54) Title: ELECTROCHEMICAL-BASED ANALYTICAL TEST STRIP WITH INTERSECTING SAMPLE-RECEIVING CHAMBERS

(57) Abstract: An electrochemical-based analytical test strip for the determination of an analyte (such as glucose) in a bodily fluid sample (for example, a whole blood sample) and/or a characteristic of the bodily fluid sample (for example, hematocrit) includes a first sample-receiving chamber with first and second sample-application openings, and first and second electrodes. The first and second electrodes are disposed in the first sample-receiving chamber between the first and second sample-application openings. The electrochemical-based analytical test strip also includes a second sample-receiving chamber and a plurality of electrodes disposed in the second sample-receiving chamber. In addition, the second sample-receiving chamber intersects the first sample-receiving chamber between the first and second electrodes, thereby defining a chamber intersection.

## ELECTROCHEMICAL-BASED ANALYTICAL TEST STRIP WITH INTERSECTING SAMPLE-RECEIVING CHAMBERS

### BACKGROUND OF THE INVENTION

#### [0001] Field of the Invention

[0002] The present invention relates, in general, to medical devices and, in particular, to analytical test strips and related methods.

#### [0003] Description of Related Art

[0004] The determination (e.g., detection and/or concentration measurement) of an analyte in a fluid sample is of particular interest in the medical field. For example, it can be desirable to determine glucose, ketone bodies, cholesterol, lipoproteins, triglycerides, acetaminophen and/or HbA1c concentrations in a sample of a bodily fluid such as urine, blood, plasma or interstitial fluid. Such determinations can be achieved using analytical test strips, based on, for example, visual, photometric or electrochemical techniques. Conventional electrochemical-based analytical test strips are described in, for example, U.S. Patent Nos. 5,708,247, and 6,284,125, each of which is hereby incorporated in full by reference.

### BRIEF DESCRIPTION OF THE DRAWINGS

[0005] The accompanying drawings, which are incorporated herein and constitute part of this specification, illustrate presently preferred embodiments of the invention, and, together with the general description given above and the detailed description given below, serve to explain features of the invention, in which:

FIG. 1 is a simplified exploded view of an electrochemical-based analytical test strip according to an embodiment of the present invention;

FIG. 2 is a sequence of simplified top views of the various layers of the electrochemical-based analytical test strip of FIG. 1;

FIG. 3 is a simplified top view representation of a portion of a patterned conductor layer of the electrochemical-based analytical test strip of FIG. 1;

FIG. 4 is a simplified top view of the portion of the patterned conductor layer and an enzymatic reagent layer of the electrochemical-based analytical test strip of FIG. 1 with the reagent layer depicted as partially transparent to highlight the patterned conductor layer there under;

FIG. 5 is a simplified top view of the portion of the patterned conductor layer, the enzymatic reagent layer and a portion of a patterned spacer layer of the electrochemical-based analytical test strip of FIG. 1; and

FIG. 6 is a flow diagram depicting stages in a method for determining an analyte in a bodily fluid sample according to an embodiment of the present invention.

#### **DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS**

**[0006]** The following detailed description should be read with reference to the drawings, in which like elements in different drawings are identically numbered. The drawings, which are not necessarily to scale, depict exemplary embodiments for the purpose of explanation only and are not intended to limit the scope of the invention. The detailed description illustrates by way of example, not by way of limitation, the principles of the invention. This description will clearly enable one skilled in the art to make and use the invention, and describes several embodiments, adaptations, variations, alternatives and uses of the invention, including what is presently believed to be the best mode of carrying out the invention.

[0007] As used herein, the terms “about” or “approximately” for any numerical values or ranges indicate a suitable dimensional tolerance that allows the part or collection of components to function for its intended purpose as described herein.

[0008] As used herein, the terms “intersect” and “intersecting” refers to entities (such as a first sample-receiving chamber and a second sample-receiving chamber) forming an intersection with each other; crossing each other, or overlapping each other. In addition, as used herein, the term “intersection” refers to a point or set of points common to two or more geometric entities (such as two sample-receiving chambers).

[0009] In general, an electrochemical-based analytical test strip for the determination of an analyte (such as glucose) in a bodily fluid sample (for example, a whole blood sample) and/or a characteristic of the bodily fluid sample (for example, hematocrit) includes a first sample-receiving chamber with first and second sample-application openings, and first and second electrodes. The first and second electrodes are disposed in the first sample-receiving chamber between the first and second sample-application openings. The electrochemical-based analytical test strip also includes a second sample-receiving chamber and a plurality of electrodes disposed in the second sample-receiving chamber. In addition, the second sample-receiving chamber intersects the first sample-receiving chamber between the first and second electrodes, thereby defining a chamber intersection.

[0010] Electrochemical-based analytical test strips according to embodiments of the present invention are beneficial in that, for example, a relatively small volume of bodily fluid sample (for example, a bodily fluid sample of approximately 1.3 micro-liters) can be employed to fill both the first and second sample-receiving chambers. Such a relatively small bodily fluid sample is enabled since the chamber intersection serves as the bodily fluid sample entrance to the second sample-receiving chamber and either of the first and second sample-application

openings can be employed to apply a bodily fluid sample that fills both the first and the second sample-receiving chambers. In addition, since the first and second electrodes disposed in the first sample-receiving chamber are on either side of the chamber intersection, a beneficially large separation of the first and second electrodes is achieved while maintaining a low bodily fluid sample volume. Moreover, electrochemical-based analytical test strips according to embodiments of the present invention can be manufactured using relatively inexpensive and simple conventional processes and materials.

[0011] FIG. 1 is a simplified exploded view of an electrochemical-based analytical test strip 100 according to an embodiment of the present invention. FIG. 2 is a sequence of simplified top views of various layers of electrochemical-based analytical test strip 100. FIG. 3 is a simplified top view of a portion of a patterned conductor layer of electrochemical-based analytical test strip 100. FIG. 4 is a simplified top view of a portion of the patterned conductor layer and an enzymatic reagent layer of electrochemical-based analytical test strip 100, with the enzymatic reagent layer depicted as partially transparent to highlight the patterned conductor layer thereunder. FIG. 5 is a simplified top view of the portion of the patterned conductor layer, the enzymatic reagent layer and a portion of a patterned spacer layer of electrochemical-based analytical test strip 100.

[0012] Referring to FIGs. 1-5, electrochemical-based analytical test strip 100 for the determination of an analyte (such as glucose) in a bodily fluid sample (for example, a whole blood sample) includes an electrically-insulating substrate layer 110, a patterned conductor layer 120, an enzymatic reagent layer 130, a patterned spacer layer 140, a hydrophilic layer 150, and a top layer 160.

[0013] The disposition and alignment of electrically-insulating substrate layer 110, patterned conductor layer 120 (which includes a first electrode 120a, second electrode 120b, working electrode 120c, working electrode 120d and

counter/reference electrode 120e; see FIGs. 4 and 5 in particular), patterned spacer layer 140, hydrophilic layer 150 and top layer 160 of electrochemical-based analytical test strip 100 are such that a first sample-receiving chamber 162 and a second sample-receiving chamber 164 are defined within electrochemical-based analytical test strip 100. Moreover, first sample-receiving chamber 162 includes a first sample-application opening 166 and a second sample-application opening 168.

[0014] In the embodiment of FIGs. 1-5, first electrode 120a is disposed in the first sample-receiving chamber 162 between the first sample-application opening 166 and the second sample-application opening 168 and second electrode 120b disposed in first sample-receiving chamber 162 between the first sample-application opening 166 and the second sample-application opening 168. Moreover, second sample-receiving chamber 164 intersects the first sample-receiving chamber 162 between the first electrode 120a and the second electrode 120b, thereby defining a chamber intersection 170 in electrochemical-based analytical test strip 100. In addition, electrodes 120c, 120d, and 120e are operatively disposed in second sample-receiving chamber 164.

[0015] Although, for the purpose of explanation only, electrochemical-based analytical test strip 100 is depicted as including a total of five electrodes, embodiments of electrochemical-based analytical test strips, including embodiments of the present invention, can include any suitable number of electrodes. First and second electrodes 120a and 120b, respectively, can have areas of, for example, 0.23 square-mm. Working electrodes 120c and 120d can each have, for example, an area of 0.28 square-mm and counter/reference electrode 120e can have, for example, an area of 0.56 square-mm. The distance between the midpoints of the first and second electrodes (i.e., in the left-to-right direction of FIG. 5) is, for example, 4.60mm.

[0016] Patterned conductor layer 120, including electrodes 120a, 120b, 120c, 120d and 120e, of analytical test strip 100 can be formed of any suitable material including, for example, gold, palladium, platinum, indium, titanium-palladium alloys and electrically conducting carbon-based materials including carbon inks. Referring in particular to FIG. 5, the disposition of first working electrode 120c, second working electrode 120d and counter/reference electrode 120e and enzymatic reagent layer 130 are such that analytical test strip 100 is configured for the electrochemical determination of an analyte (glucose) in a bodily fluid sample (whole blood) that has filled second sample-receiving chamber 164.

[0017] Moreover, first electrode 120a and second electrode 120b are disposed in first sample-receiving chamber 162 such that electrochemical-based analytical test strip 100 is configured for the determination of haematocrit in a whole blood sample that has filled first sample-receiving chamber 162. During use, a bodily fluid sample is applied to electrochemical-based analytical test strip 100 and transferred to both first sample-receiving chamber 162 (thereby operatively contacting the first and second electrodes 120a and 120b) and to the second sample-receiving chamber 164, thereby operatively contacting electrodes 120c, 120d and 120e. The determination of haematocrit using electrodes of an analytical test strip is described in, for example, U.S. Patent Application Nos. 61/581,100; 61/581,097; 61/581,089; 61/530,795 and 61/530,808, each of which is hereby incorporated in full by reference.

[0018] Chamber intersection 170 is configured to serve both as a portion of first sample-receiving chamber 162 and as a sample entrance for second sample-receiving chamber 164. Such a configuration beneficially minimizes the volume of the first and second sample-receiving chamber. Moreover, since first sample-receiving chamber 162 is reagent-less (i.e., enzymatic reagent layer 130 is not disposed within first sample-receiving chamber 162), there is no risk of a bodily fluid sample that flows through first sample-receiving chamber inadvertently introducing an unwanted reagent into the second sample-receiving chamber.

[0019] In the embodiment of FIGs. 1 through 5, the first sample-receiving chamber 162 and second sample-receiving chamber 164 are disposed in an essentially T-shaped configuration. Such a T-shaped configuration enables first and second sample-application openings 166 and 168 to be disposed on opposing lateral edges of electrochemical-based analytical test strip 100. A user is thus enabled to choose either of the sample-application openings for application of a bodily fluid sample. In the perspective of FIG. 5, first sample-receiving chamber 162 has a width (in the vertical direction of the perspective of FIG. 5) of, for example, 0.75 microns while second sample-receiving chamber 164 has a width (in the horizontal direction of the perspective of FIG. 5) in the vicinity of the electrodes of, for example, 1.3 microns.

[0020] A benefit of the T-shaped configuration depicted in, for example, FIGs. 1, 2 and 5 is that the T-shape is symmetrical about a vertical center-line (in the perspective of FIG. 5) of the electrochemical-based analytical test strip. Therefore, it is postulated without being bound that the performance of electrochemical-based analytical test strip 100 would be beneficially identical regardless of whether the first sample-application opening 166 or the second sample-application opening 168 is employed during sample application.

[0021] Electrically-insulating substrate layer 110 can be any suitable electrically-insulating substrate layer known to one skilled in the art including, for example, a nylon substrate, polycarbonate substrate, a polyimide substrate, a polyvinyl chloride substrate, a polyethylene substrate, a polypropylene substrate, a glycolated polyester (PETG) substrate, or a polyester substrate. The electrically-insulating substrate layer can have any suitable dimensions including, for example, a width dimension of about 5 mm, a length dimension of about 27 mm and a thickness dimension of about 0.5 mm.

[0022] Electrically-insulating substrate layer 110 provides structure to electrochemical-based analytical test strip 100 for ease of handling and also serves as a base for the application (e.g., printing or deposition) of subsequent layers (e.g., a patterned conductor layer). It should be noted that patterned conductor layers employed in analytical test strips according to embodiments of the present invention can take any suitable shape and be formed of any suitable materials including, for example, metal materials and conductive carbon materials.

[0023] Patterned spacer layer 140 can be formed, for example, from a screen-printable pressure sensitive adhesive commercially available from Apollo Adhesives, Tamworth, Staffordshire, UK. In the embodiment of FIGs. 1 through 5, patterned spacer layer 140 defines outer walls of the first sample-receiving chamber 162 and the second sample-receiving chamber 164. Patterned spacer layer 140 can have a thickness of, for example, approximately 130 microns.

[0024] Hydrophilic layer 150 can be, for example, a clear film with hydrophilic properties that promote wetting and filling of electrochemical-based analytical test strip 100 by a fluid sample (e.g., a whole blood sample). Such clear films are commercially available from, for example, 3M of Minneapolis, Minnesota U.S.A. and Coveme (San Lazzaro di Savena, Italy). Hydrophilic layer 150 can be, for example, a polyester film coated with a surfactant that provides a hydrophilic contact angle < 10 degrees. Hydrophilic layer 150 can also be a polypropylene film coated with a surfactant or other surface treatment, e.g., a MESA coating. Hydrophilic layer 150 can have a thickness, for example, of approximately 100um. Moreover, in the embodiment of FIGs. 1-5, hydrophilic layer 150 is patterned to provide an air vent for second sample-receiving chamber 164 (as depicted by the alignment of the patterned hydrophilic layer 150 and patterned spacer layer 140 in FIGs. 1 and 2).

[0025] Enzymatic reagent layer 130 can include any suitable enzymatic reagents, with the selection of enzymatic reagents being dependent on the analyte to be determined. For example, if glucose is to be determined in a blood sample, enzymatic reagent layer 130 can include a glucose oxidase or glucose dehydrogenase along with other components necessary for functional operation. Enzymatic reagent layer 130 can include, for example, glucose oxidase, tri-sodium citrate, citric acid, polyvinyl alcohol, hydroxyl ethyl cellulose, potassium ferrocyanide, antifoam, cabosil, PVPVA, and water. Further details regarding enzymatic reagent layers, and electrochemical-based analytical test strips in general, are in U.S. Patent Nos. 6,241,862 and 6,733,655, the contents of which are hereby fully incorporated by reference.

[0026] Electrochemical-based analytical test strip 100 can be manufactured, for example, by the sequential aligned formation of patterned conductor layer 120, enzymatic reagent layer 130, patterned spacer layer 140, hydrophilic layer 150 and top layer 160 onto electrically-insulating substrate layer 110. Any suitable techniques known to one skilled in the art can be used to accomplish such sequential aligned formation, including, for example, screen printing, photolithography, photogravure, chemical vapour deposition and tape lamination techniques.

[0027] FIG. 6 is a flow diagram depicting stages in a method 600 for determining an analyte (such as glucose) in a bodily fluid sample (for example, a whole blood sample) and/or a characteristic of the bodily fluid sample (e.g., hematocrit) according to an embodiment of the present invention. Method 600 includes (see step 610 of FIG. 6) applying a bodily fluid sample to either of a first sample-application opening and a second sample-application opening of a first sample-receiving chamber of an electrochemical-based analytical test strip such that the applied bodily fluid sample fills the first sample-receiving chamber and a second-sample-receiving chamber of the electrochemical-based analytical test strip.

[0028] Method 600 also includes measuring a first response of the electrochemical-based analytical test strip (for example an electrochemical response from electrodes in the second sample-receiving chamber) and determining an analyte in the bodily fluid sample is determined based on the measured first response (see steps 620 and 630 of FIG. 6).

[0029] In steps 640 and 650 of method 600 also includes, measuring a second response of the electrochemical-based analytical test strip (for example, an electrical response from electrodes in the first sample-receiving chamber) and determining a characteristic of the bodily fluid sample (such as hematocrit or other bodily fluid sample characteristic that can be determined in a reagent-less manner) based on the second measured response. Alternatively, since the first sample-receiving chamber is reagent-less, steps 640 and 650 can be employed to measure a second analyte (such as, for example, uric acid, acetaminophen or dopamine) of the bodily fluid sample in a reagent-less manner. The measuring and determination steps described above can, if desired, be performed using a suitable associated meter and measurement steps 620 and 630 can be performed in any suitable sequence or in an overlapping manner.

[0030] Once apprised of the present disclosure, one skilled in the art will recognize that method 600 can be readily modified to incorporate any of the techniques, benefits and characteristics of electrochemical-based analytical test strips according to embodiments of the present invention and described herein.

[0031] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope

of the invention and that devices and methods within the scope of these claims and their equivalents be covered thereby.

**CLAIMS****WHAT IS CLAIMED IS:**

1. An electrochemical-based analytical test strip for the determination of an analyte in a bodily fluid sample, the electrochemical-based analytical test strip comprising:
  - a first sample-receiving chamber with:
    - a first sample-application opening; and
    - a second sample-application opening;
  - a first electrode disposed in the first sample-receiving chamber between the first sample-application opening and the second sample-application opening;
  - a second electrode disposed in the first sample-receiving chamber between the first sample-application opening and the second sample-application opening;
  - a second sample-receiving chamber that intersects the first sample-receiving chamber between the first electrode and the second electrode, thereby defining a chamber intersection, and
    - at least a third electrode disposed in the second sample-receiving chamber.
2. The electrochemical-based analytical test strip of claim 1 wherein the chamber intersection is between the first sample-application opening and the second sample-application opening.
3. The electrochemical-based analytical test strip of claim 1 wherein the first capillary sample-receiving chamber and second capillary sample-receiving chamber are disposed in an essentially T-shaped configuration.
4. The electrochemical-based analytical test strip of claim 3 wherein the T-shaped configuration is symmetrical about a vertical centerline of the

electrochemical-based analytical test strip.

5. The electrochemical-based analytical test strip of claim 1 wherein the second sample-receiving chamber has a sample entrance, and  
wherein the chamber intersection is configured as the sample entrance of the second sample-receiving chamber.

6. The electrochemical-based analytical test strip of claim 1, further comprising:
  - an electrically insulating substrate layer;
  - a patterned conductor layer disposed over the electrically-insulating substrate layer, the patterned conductive layer including the first, second and at least third electrodes;
  - an enzymatic reagent layer disposed over the patterned conductor layer;
  - a patterned spacer layer;
  - a hydrophilic layer; and
  - a top layer,

wherein the electrically insulating substrate layer, patterned spacer layer, the hydrophilic layer and the top layer essentially define the first sample-receiving chamber, the second sample-receiving chamber, the first sample-application opening and the second-sample application opening.

7. The electrochemical-based analytical test strip of claim 1 wherein the first sample-application opening and the second sample-application opening are on opposing lateral sides of the electrochemical-based analytical test strip.

8. The electrochemical-based analytical test strip of claim 1 wherein the first sample-receiving chamber is a reagent-less sample-receiving chamber.

9. The electrochemical-based analytical test strip of claim 1 wherein the first electrode and second electrode are configured for the determination of hematocrit of a

bodily fluid sample in the first sample-receiving chamber.

10. The electrochemical-based analytical test strip of claim 1 wherein the at least third electrode includes a first working electrode, a second working electrode and a counter/reference electrode.

11. The electrochemical-based analytical test strip of claim 10 wherein the first working electrode, a second working electrode and a counter/reference electrode are configured for the determination of an analyte of a bodily fluid sample in the second sample-receiving chamber.

12. The electrochemical-based analytical test strip of claim 11 wherein the analyte is glucose and the bodily fluid sample is blood.

13. A method for determining an analyte in a bodily fluid sample, the method comprising:

applying a bodily fluid sample to either of a first sample-application opening and a second sample-application opening of a first sample-receiving chamber of an electrochemical-based analytical test strip such that the applied bodily fluid sample fills the first sample-receiving chamber and a second-sample-receiving chamber of the electrochemical-based analytical test strip,

measuring a first response of the electrochemical-based analytical test strip that is dependent on bodily fluid sample in the second sample-receiving chamber; and

determining the analyte based on the measured electrochemical response.

14. The method of claim 13 further including:

measuring a second response of the analytical test strip that is dependent on bodily fluid sample in the first capillary sample-receiving chamber; and

determining a characteristic of the bodily fluid sample based on the second

measured response.

15. The method of claim 13 wherein the bodily fluid sample is whole blood.

16. The method of claim 15 wherein the analyte is glucose.

17. The method of claim 15 wherein the characteristic is hematocrit.

18. The method of claim 13 wherein:

a first electrode is disposed in the first sample-receiving chamber between the first sample-application opening and the second sample-application opening,

a second electrode is disposed in the first sample-receiving chamber between the first sample-application opening and the second sample-application opening;

the second sample-receiving chamber intersects the first sample-receiving chamber between the first electrode and the second electrode, thereby defining a chamber intersection, and

at least a third electrode disposed in the second sample-receiving chamber.

19. The method of claim 18 wherein the chamber intersection is between the first sample-application opening and the second sample-application opening.

20. The method of claim 19 wherein the first capillary sample-receiving chamber and second capillary sample-receiving chamber are disposed in an essentially T-shaped configuration.

21. The method of claim 18 wherein the second sample-receiving chamber has a sample entrance, and


wherein the chamber intersection is configured as the sample entrance of

the second sample-receiving chamber.


22. The method of claim 18 wherein the first sample-application opening and the second sample-application opening are on opposing lateral sides of the electrochemical-based analytical test strip.

23. The method of claim 19 wherein the first sample-receiving chamber is a reagent-less sample-receiving chamber.




1/4




2/4



3/4

**FIG. 3****FIG. 4****FIG. 5**

4/4

**FIG. 6**

# INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2013/062950

**A. CLASSIFICATION OF SUBJECT MATTER**  
INV. C12Q1/00  
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, EMBASE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2011/155589 A1 (CHATELIER RONALD C [AU] ET AL) 30 June 2011 (2011-06-30) paragraph [0018] - paragraph [0025]	1-23
Y	----- US 8 012 428 B2 (DILLEEN JOHN WILLIAM [GB] ET AL) 6 September 2011 (2011-09-06) figures 1-4	1-23
Y	----- EP 1 304 570 A1 (BIOPTIK TECH INC [CN]) 23 April 2003 (2003-04-23) figure 3A	1-23
Y	----- US 2005/023136 A1 (LEACH CHRISTOPHER PHILIP [GB] ET AL) 3 February 2005 (2005-02-03) figures 1-6	1-23
	----- -/-	

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
8 August 2013	16/08/2013

Name and mailing address of the ISA/  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

Authorized officer

Rosin, Oliver

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2013/062950

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2005/001462 A1 (ROCHE DIAGNOSTICS GMBH [DE]; HOFFMANN LA ROCHE [CH]; BURKE DAVID W [US] 6 January 2005 (2005-01-06) figure 17 -----	1-23
2		

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/EP2013/062950
---

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
US 2011155589	A1 30-06-2011	AU AU BR CA CN EP JP KR SG TW US US	2010257393 A1 2010257465 A1 PI1010355 A2 2726411 A1 102116752 A 2360477 A1 2011145291 A 20110079561 A 172589 A1 201128191 A 2011155585 A1 2011155589 A1		14-07-2011 14-07-2011 18-12-2012 30-06-2011 06-07-2011 24-08-2011 28-07-2011 07-07-2011 28-07-2011 16-08-2011 30-06-2011 30-06-2011
US 8012428	B2 06-09-2011	BR CA CN EP ES HK JP RU US	PI0904420 A2 2684158 A1 101788518 A 2182355 A2 2395483 T3 1142129 A1 2010107512 A 2009140135 A 2010112678 A1		21-09-2010 30-04-2010 28-07-2010 05-05-2010 13-02-2013 21-06-2013 13-05-2010 10-05-2011 06-05-2010
EP 1304570	A1 23-04-2003	NONE			
US 2005023136	A1 03-02-2005	NONE			
WO 2005001462	A1 06-01-2005	CA EP JP JP US US US US WO	2530300 A1 1639357 A1 2007524817 A 2010078614 A 2004260511 A1 2009089010 A1 2009292489 A1 2011241694 A1 2005001462 A1		06-01-2005 29-03-2006 30-08-2007 08-04-2010 23-12-2004 02-04-2009 26-11-2009 06-10-2011 06-01-2005